Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry J M Groen

Showing results (51-60 of 274) with videos related to

Pageof 28
Sort By:
Cancer Chemotherapy and Pharmacology|March 21, 2003
Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokineticsJan Gerard Maring, Henk Piersma, Albert van Dalen, et al.
Therapeutic Drug Monitoring|March 26, 2010
Gemcitabine and epirubicin plasma concentration-related excretion in saliva in patients with non-small cell lung cancerJan Gerard Maring, Floris M Wachters, Marina Maurer, et al.
Respiratory Medicine|February 18, 2005
Technical description of endoscopic ultrasonography with fine-needle aspiration for the staging of lung cancerHenk Kramer, John W G van Putten, W Rob Douma, et al.
Clinical Drug Investigation|July 9, 2025
Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term SurvivorsZakile A Mfumbilwa, Janneke A Wilschut, Harry J M Groen, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2003
Selective targeting of homologous DNA recombination repair by gemcitabineFloris M Wachters, John W G van Putten, Jan G Maring, et al.
European Journal of Cancer (Oxford, England : 1990)|March 6, 2022
A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the NetherlandsDeirdre M H J Ten Berge, Mieke J Aarts, Harry J M Groen, et al.
Journal for Immunotherapy of Cancer|July 12, 2019
Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitorsMenno Tamminga, Sanne de Wit, T Jeroen N Hiltermann, et al.
Diagnostics (Basel, Switzerland)|March 25, 2022
Detection of <i>NTRK</i> Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based CohortBart Koopman, Chantal C H J Kuijpers, Harry J M Groen, et al.
Translational Lung Cancer Research|February 4, 2020
Circulating tumor cells in lung cancer are prognostic and predictive for worse tumor response in both targeted- and chemotherapyMenno Tamminga, Sanne de Wit, Ed Schuuring, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 3, 2007
Prognostic value of different metabolic measurements with fluorine-18 fluorodeoxyglucose positron emission tomography in resectable non-small cell lung cancer: a two-center studyWouter K de Jong, Henricus F M van der Heijden, Jan Pruim, et al.
Pageof 28

Showing results (51-60 of 274) with videos related to

Sort By:
Pageof 28
Cancer Chemotherapy and Pharmacology|March 21, 2003
Extensive hepatic replacement due to liver metastases has no effect on 5-fluorouracil pharmacokineticsJan Gerard Maring, Henk Piersma, Albert van Dalen, et al.
Therapeutic Drug Monitoring|March 26, 2010
Gemcitabine and epirubicin plasma concentration-related excretion in saliva in patients with non-small cell lung cancerJan Gerard Maring, Floris M Wachters, Marina Maurer, et al.
Respiratory Medicine|February 18, 2005
Technical description of endoscopic ultrasonography with fine-needle aspiration for the staging of lung cancerHenk Kramer, John W G van Putten, W Rob Douma, et al.
Clinical Drug Investigation|July 9, 2025
Cost-Effectiveness of Pembrolizumab Monotherapy for High Programmed Death Ligand 1 Advanced or Metastatic Non-small Cell Lung Cancer Depends on Long-Term SurvivorsZakile A Mfumbilwa, Janneke A Wilschut, Harry J M Groen, et al.
International Journal of Radiation Oncology, Biology, Physics|September 6, 2003
Selective targeting of homologous DNA recombination repair by gemcitabineFloris M Wachters, John W G van Putten, Jan G Maring, et al.
European Journal of Cancer (Oxford, England : 1990)|March 6, 2022
A population-based study describing characteristics, survival and the effect of TKI treatment on patients with EGFR mutated stage IV NSCLC in the NetherlandsDeirdre M H J Ten Berge, Mieke J Aarts, Harry J M Groen, et al.
Journal for Immunotherapy of Cancer|July 12, 2019
Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitorsMenno Tamminga, Sanne de Wit, T Jeroen N Hiltermann, et al.
Diagnostics (Basel, Switzerland)|March 25, 2022
Detection of <i>NTRK</i> Fusions and TRK Expression and Performance of pan-TRK Immunohistochemistry in Routine Diagnostics: Results from a Nationwide Community-Based CohortBart Koopman, Chantal C H J Kuijpers, Harry J M Groen, et al.
Translational Lung Cancer Research|February 4, 2020
Circulating tumor cells in lung cancer are prognostic and predictive for worse tumor response in both targeted- and chemotherapyMenno Tamminga, Sanne de Wit, Ed Schuuring, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 3, 2007
Prognostic value of different metabolic measurements with fluorine-18 fluorodeoxyglucose positron emission tomography in resectable non-small cell lung cancer: a two-center studyWouter K de Jong, Henricus F M van der Heijden, Jan Pruim, et al.
Pageof 28